Zepbound is Eli Lilly's brand of tirzepatide for chronic weight management (November 2023) and moderate-to-severe OSA in adults with obesity (December 2024). LillyDirect sells single-dose vials for self-pay starting at $299 a month.
At a glance
- Generic name: tirzepatide
- Manufacturer: Eli Lilly
- List price: about $1,086 a month (manufacturer list price, before insurance or discounts)
- Self-pay via LillyDirect vials (read October 15, 2026): $299 (2.5 mg), $399 (5 mg) and $449 (7.5 to 15 mg) when each refill is within 45 days; otherwise $499 at 7.5 mg and $699 at 10 to 15 mg
- Medicare: Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027): a $50 copay for eligible Part D enrollees for Foundayo, Wegovy or the Zepbound KwikPen; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible and use their Part D plan instead.
FDA-approved indications
- Chronic weight management (November 2023)
- Moderate-to-severe OSA in adults with obesity (December 2024) — first drug FDA-approved for OSA
August 2026 label update: the diabetic-retinopathy warning (section 5.8) now says patients with a history of diabetic retinopathy should be monitored for progression. The August 2026 cardiovascular indication applies to Mounjaro (type 2 diabetes), not Zepbound.
Standard dosing
- Start: 2.5 mg/wk × 4 wk
- Titration: 5 → 7.5 → 10 → 12.5 → 15 mg
- Maintenance: 5, 10, or 15 mg weekly